In a significant move to expand its peptide manufacturing capabilities CordenPharma has announced plans to establish a state-of-the-art facility at Getec Park in Muttenz, Switzerland, located just 8 km outside Basel. This strategic location places the facility within one of Europe’s leading biotech and pharmaceutical hubs, offering access to advanced infrastructure, skilled talent, and sustainable operational practices.
Key Highlights of the New Facility
- Investment:
- The project represents a €500 million investment, underscoring CordenPharma’s commitment to innovation and growth in the peptide manufacturing sector.
- Production Capacity:
- The facility will feature multiple manufacturing lines capable of supporting small, medium, and large-scale peptide production.
- It will include Solid Phase Peptide Synthesis (SPPS) reactors with a total capacity of over 5,000 liters, catering to both GLP-1 and non-GLP-1 peptide projects.
- Advanced Technologies:
- The facility will incorporate advanced automation, cutting-edge digitalization, and innovative peptide production technologies.
- It will ensure compliance with stringent regulatory requirements, including Biologics License Application (BLA) standards.
- Sustainability:
- Located within Getec Park, the facility will benefit from closed-loop systems and waste-to-value streams, promoting sustainable operations.
Strategic Location and Economic Impact
- Proximity to Basel: The facility’s location near Basel, a major biotech and pharma hub, provides access to efficient infrastructure, optimal logistics, and a highly skilled workforce.
- Job Creation: The project is expected to generate over 300 new jobs, contributing to the region’s economic growth and innovation.
Timeline and Operational Plans
- Construction and Qualification: The main construction and qualification phase will take place between 2025 and 2027.
- Commercial Operations: The facility is expected to begin commercial activities in the first half of 2028.
Leadership’s Vision
Dr. Michael Quirmbach, President & CEO of CordenPharma Group, expressed his enthusiasm for the project:
“We are excited to announce the construction of a state-of-the-art manufacturing plant just outside Basel, Switzerland, within one of the leading pharma and biotech hubs in Europe. The new facility is designed to deliver flexible and efficient peptide manufacturing to meet the growing demand for innovative peptide medicines for our customers and, ultimately, patients.”
Strengthening CordenPharma’s Position
Once fully operational, the new facility will significantly enhance CordenPharma’s production capabilities, solidifying its position as one of the largest peptide manufacturing partners in the Contract Development and Manufacturing Organization (CDMO) space.
Conclusion
CordenPharma’s €500 million investment in Switzerland marks a major milestone in the company’s growth strategy. By leveraging advanced technologies, sustainable practices, and a strategic location, the new facility will play a crucial role in meeting the growing demand for peptide-based medicines.
As CordenPharma continues to expand its global footprint, this project reinforces its commitment to innovation, quality, and patient-centric solutions in the pharmaceutical and biotech industries
